Gulanbar Amori1,2, Emiko Sugawara1,2, Yasuyuki Shigematsu1,2, Masashi Akiya1,2, Junko Kunieda1,3, Takeshi Yuasa4, Shinya Yamamoto4, Junji Yonese4, Kengo Takeuchi1,2,5, Kentaro Inamura6,7. 1. Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. 2. Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 3. Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. 4. Department of Urology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 5. Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. 6. Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. kentaro.inamura@jfcr.or.jp. 7. Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. kentaro.inamura@jfcr.or.jp.
Abstract
BACKGROUND: Prostate cancer spans a broad spectrum from indolent to deadly disease. In the management of prostate cancer, diagnostic biopsy specimens are important sources of data that inform the selection of treatment. B7-H3 (CD276), an immune checkpoint molecule, has emerged as a promising immunotherapy target. B7-H3 expression is related to adverse clinical outcomes in various types of cancer; however, little is known concerning the association between tumor B7-H3 expression in diagnostic biopsy specimens and clinical outcome in patients with metastatic prostate cancer. METHODS: We evaluated tumor B7-H3 expression levels in diagnostic biopsy specimens from 135 patients with metastatic prostate cancer and 113 patients with localized prostate cancer. RESULTS: High B7-H3 expression was more frequently observed in patients with metastatic cancer than in those with localized cancer (31 vs. 12%; p = 0.0003). In patients with localized cancer, the B7-H3 expression status was not associated with biochemical recurrence-free survival. However, among patients with metastatic cancer, high B7-H3 expression was independently associated with high disease-specific mortality (multivariable hazard ratio [HR] = 2.72; p = 0.047) and overall mortality rates (multivariable HR = 2.04; p = 0.025). CONCLUSIONS: Tumor B7-H3 expression in diagnostic biopsy specimens may be a useful biomarker for identifying highly aggressive metastatic prostate cancer. Given the potential utility of anti-B7-H3 immunotherapy, this information may aid in stratifying prostate cancer based on its responsiveness to B7-H3-targeted treatment.
BACKGROUND: Prostate cancer spans a broad spectrum from indolent to deadly disease. In the management of prostate cancer, diagnostic biopsy specimens are important sources of data that inform the selection of treatment. B7-H3 (CD276), an immune checkpoint molecule, has emerged as a promising immunotherapy target. B7-H3 expression is related to adverse clinical outcomes in various types of cancer; however, little is known concerning the association between tumor B7-H3 expression in diagnostic biopsy specimens and clinical outcome in patients with metastatic prostate cancer. METHODS: We evaluated tumor B7-H3 expression levels in diagnostic biopsy specimens from 135 patients with metastatic prostate cancer and 113 patients with localized prostate cancer. RESULTS: High B7-H3 expression was more frequently observed in patients with metastatic cancer than in those with localized cancer (31 vs. 12%; p = 0.0003). In patients with localized cancer, the B7-H3 expression status was not associated with biochemical recurrence-free survival. However, among patients with metastatic cancer, high B7-H3 expression was independently associated with high disease-specific mortality (multivariable hazard ratio [HR] = 2.72; p = 0.047) and overall mortality rates (multivariable HR = 2.04; p = 0.025). CONCLUSIONS: Tumor B7-H3 expression in diagnostic biopsy specimens may be a useful biomarker for identifying highly aggressive metastatic prostate cancer. Given the potential utility of anti-B7-H3 immunotherapy, this information may aid in stratifying prostate cancer based on its responsiveness to B7-H3-targeted treatment.
Authors: Jose R Castellanos; Ian J Purvis; Collin M Labak; Maheedhara R Guda; Andrew J Tsung; Kiran K Velpula; Swapna Asuthkar Journal: Am J Clin Exp Immunol Date: 2017-06-15
Authors: Steven Seaman; Zhongyu Zhu; Saurabh Saha; Xiaoyan M Zhang; Mi Young Yang; Mary Beth Hilton; Karen Morris; Christopher Szot; Holly Morris; Deborah A Swing; Lino Tessarollo; Sean W Smith; Sylvia Degrado; Dmitry Borkin; Nareshkumar Jain; Julia Scheiermann; Yang Feng; Yanping Wang; Jinyu Li; Dean Welsch; Gary DeCrescenzo; Amit Chaudhary; Enrique Zudaire; Kimberly D Klarmann; Jonathan R Keller; Dimiter S Dimitrov; Brad St Croix Journal: Cancer Cell Date: 2017-04-10 Impact factor: 31.743
Authors: Adeline N Boettcher; Ahmed Usman; Alicia Morgans; David J VanderWeele; Jeffrey Sosman; Jennifer D Wu Journal: Front Oncol Date: 2019-09-11 Impact factor: 6.244
Authors: Pengfei Xu; Logan J Wasielewski; Joy C Yang; Demin Cai; Christopher P Evans; William J Murphy; Chengfei Liu Journal: Biomedicines Date: 2022-07-22